Abbott Laboratories Beats on Q2 Estimates, But Stock Slides
Although it's popular as a coronavirus stock these days, Abbot Laboratories (NYSE: ABT) nevertheless is struggling with other areas of its business. This was revealed in the company's second quarter of fiscal 2020 results, which it published Thursday morning.
The quarter saw the healthcare mainstay's total sales fall by 8% on a year-over-year basis to $7.33 billion. Non-GAAP (adjusted) net earnings declined at a 47% clip, meanwhile, to $537 million, or $0.57 per share.
Image source: Getty Images.
Source Fool.com
